A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome-Reference-Cited by-同舟云学术

A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome

Published:2022-03-30 Issue:3 Volume:149 Page:1145-1158
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

DiNardo Courtney D.^ORCID,Hochhaus Andreas,Frattini Mark G.,Yee Karen,Zander Thomas,Krämer Alwin,Chen Xueying,Ji Yan,Parikh Nehal S.,Choi Joanne,Wei Andrew H.

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-03983-6.pdf

Reference32 articles.

1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224(3):334–343. https://doi.org/10.1002/path.2913

2. de Botton S, Pollyea DA, Stein EM, DiNardo C, Fathi AT, Roboz GJ et al. (2015) Clinical safety and activity of AG-120, a first-in-class potent inhibitor of the IDH1 mutant protein, in a phase I study of patients with advanced IDH1-mutant hematologic malignancies. Poster presented at the 20th Annual Congress of the European Hematology Association, 11–14 June 2015, Vienna, Austria 100704: P563.

3. Cairns RA, Mak TW (2013) Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 3(7):730–741

4. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642–4649

5. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 108(2):419–425

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects;International Journal of Molecular Sciences;2024-07-19

2. Decoding mitochondria's role in immunity and cancer therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-07

3. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers;Critical Reviews in Oncology/Hematology;2024-07

4. Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application;Journal of Advanced Research;2024-04

5. Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity;Heliyon;2024-01